Practice Guidelines for the Manegement of Alzheimer's Disease

Jong Han Park; Byoung Hoon Oh; Byeong Kil Yeon; Seol-Heui Han; Il Woo Han; Guk-Hee Suh; SangYun Kim; Jae Nam Bae; Jee Hyang Chong; Jae Hong Lee

doi:10.5124/jkma.2003.46.12.1071

J Korean Med Assoc > Volume 46(12); 2003 > Article

Park, Oh, Yeon, Han, Han, Suh, Kim, Bae, Chong, and Lee: Practice Guidelines for the Manegement of Alzheimer's Disease

Special Issue

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2003; 46(12): 1071-1096.

Published online: December 31, 2003

DOI: http://dx.doi.org/10.5124/jkma.2003.46.12.1071

Practice Guidelines for the Manegement of Alzheimer's Disease

Jong Han Park, MD¹, Byoung Hoon Oh, MD², Byeong Kil Yeon, MD³, Seol-Heui Han, MD⁴, Il Woo Han, MD⁵, Guk-Hee Suh, MD³, SangYun Kim, MD⁶, Jae Nam Bae, MD⁷, Jee Hyang Chong, MD⁸, Jae Hong Lee, MD⁹

¹Catholic University of Daegu School of Medicine, Korea.

²Department of Psychiatry, Yonsei University College of Medicine, Korea.

³Department of Psychiatry, Hallym University College of Medicine, Korea.

⁴Department of Neurology, Chungbuk National University College of Medicine, Korea.

⁵Department of Neurology, Hyoja Geriatric Hospital, Korea.

⁶Department of Neurology, Seoul National University College of Medicine, Korea.

⁷Department of Psychiatry, Inha University College of Medicin, Korea.

⁸Department of Neurology, Ewha Womens University College of Medicine, Korea.

⁹Department of Neurology, University of Ulsan College of Medicine, Korea.

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. California Workgroup on guidelines for Alzheimer's disease management. Guidelines of Alzheimer's disease management 2002.

2. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154:1-39.

3. American Academy of Neurology. Practice parameter : Management of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology 2001.

4. National Institute of Clinical Excellence. Guidance on the use of Donepezil. Rivastigmine and Galantamine 2001.

5. Qizilbash N, Schneider NS, Chui H, Tariot P, Brodaty M, Kaye J, et al. Evidence-based Dementia Practice 2002;Malden: Blackwell Science Ltd.

6. Maj M, Sartorius N. Dementia, WPA Series Evidence and Experience in Psychiatry 2000;Wiley.

7. Richter RW, Richter BZ. Alzheimer's Disease 2002;Mosby.

8. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye HA, Guyther L, et al. Practice parameter:management of dementia (an evidence-based review). Neurology 2001;56:1154-1166.

9. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease:a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.

10. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State" : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.

11. Park JH, Kwon YC. Modification of the Mini-Mental State Examination for use in the elderly in a non-western society. Part I. Development of Korean version of Mini-Mental State Examination. Int J Geriatr Psychiatry 1990;5:381-387.

12. Park JH, Park YN, Ko HJ. Modification of the Mini-Mental State Examination for use in the elderly in a non-western society. Part II. Cutoff points and their diagnostic validities. Int J Geriatr Psychiatry 1991;6:875-882.

13. Giacobini E. Selective inhibitors of butyrylcholinesterase:a valid alternative for therapy of Alzheimer's disease? Drugs Aging 2001;18:891-898.

14. Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Mobius HJ, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl 2002;135-148.

15. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.

16. Peskind ER. Pharmacologic approaches to cognitive deficits in Alzheimer's disease. J Clin Psychiatry 1998;59:Suppl 9. 22-27.

17. Wilkinson DG, Hock C, Farlow M, van Baelen B, Schwalen S. Galantamine provides broad benefits in patients with advanced moderate Alzheimer's disease disease (MMSE < or = 12) for up to six months. Int J Clin Pract 2002;56:509-514.

18. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.

19. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editor. Alzheimer's disease 1999;2nd ed. Philadelphia: Lippincott Williams & Wilkins. 245-246.

20. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA 2000;283:1007-1001.

21. Pike CJ. Estrogen modulates bcl-xL expression and beta-amyloid-induced apoptosis. J Neurochem 1999;72:1552-1563.

22. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, et al. Evidence-based dementia practice 2002;Oxford: Blackwell.

23. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, et al. L-deprenyl in Alzheimer's disease:cognitive and behavioral effects. Neurology 1998;50:660-668.

24. Watts RL, Koller WC. Movement disorders 1997;McGraw-Hill. 168-169.

25. Agnoli A, Martucci N, Fabbirini G, Buckley A, Fioravanti M. Monoamine oxidase and dementia : treatment with an inhibitor of MAO-B activity. Demetia 1990;109-114.

26. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.

27. Wieraszko A, Li G, Kornecki E, Hogan MV, Ehrlich YH. Long-term potentiation in hippocampus induced by platelet-activating factor. Neuron 1993;10:553-557.

28. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion. Neurology 1996;46:1775-1776.

29. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia : a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996;8:Suppl 3. 497-500.

30. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA 1982;248(3):333-335.

31. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia:a randomized, double-blind trial. J Clin Psychiatry 1999;60(2):107-115.

32. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53(5):946-955.

33. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. The HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities:a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57(10):968-976.

34. Street JS, Clark WS, Kadam DL, Miltan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer dementia. Int J Geriatr Psychiatry 2001;16:Suppl 1. S62-S70.

35. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer's disease patients . Alzheimer Dis Assoc Disord 2002;16(2):128-130.

36. Ballard CG, O'Brien J, James I, Swann A. Dementia:management of behavioural and psychological symptoms. Nord J Psychiatry 2003;57(2):159-160.

37. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for managing Alzheimer's disease : Part II. Treatment. Am Fam Physician 2002;65(12):2525-2534.

38. Qizilbash N, Schneider LS. Evidence-based dementia practice 2002;Oxford: Blackwell. 680.

39. American Psychiatric Association. Practice guidelines for the treatment of psychiatric disorders 2000;Washington DC: APA. 108.

40. Holzer JC, Gitelman DR, Price BH. Efficacy of buspirone in the treatment of dementia with aggression. Am J Psychiatry 1995;152(5):812.

41. Gottfries CG, Nyth AL. Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann N Y Acad Sci 1991;640:276-279.

42. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86(2):138-145.

43. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease : initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000;157(10):1686-1689.

44. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13(2):100-108.

45. Raji MA, Brady SR. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother 2001;35(9):1024-1027.

46. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression:an international double-blind, placebo-controlled trial. Br J Psychiatry 1996;168(2):149-157.

47. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease:an open-label study. J Geriatr Psychiatry Neurol 1996;9(1):1-6.

48. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol 2002;25(6):313-317.

49. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 2002;127):20-36.

50. Petrie WM, Ban TA. Propranolol in organic agitation. Lancet 1981;1:324.

51. Weiler PG, Mungas D, Bernick C. Propranolol for the control of disruptive behaviour in senile dementia. J Geriatr Psychiatry Neurol 1988;1:226-230.

52. Goad DL, Davis CM, Liem P, Fuselier CC, McDormack JR, Olsen KM. The use of selegeline in Alzheimer's patients with behavior problems. J Clin Psychiatry 1991;52:342-345.

53. Schneider LS, Pollock VE, Zemansky MF, Gleason RP, Palmer R, Sloane RB. A pilot study of low-dose L-deprenyl in Alzheimer's disease. J Geriatr Psychiatry Neurol 1991;4(3):143-148.

54. Lawlor BA, Aisen PS, Green C, Fine E, Schmeidler J. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Geriatr Psychiatry 1997;12(3):319-322.

55. Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type:results of a 15-month trial. J Am Geriatr Soc 1993;41(11):1219-1225.

56. O'Brien MD. How does cerebrovascular disease cause dementia? Dementia 1994;5:133-136.

57. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimers Disease (CERAD) part X : neuropathology confirmation of the clinical diagnosis of Alzheimers disease. Neurology 1995;45:461-466.

58. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimers disease. The Nun Study. JAMA 1997;277:813-817.

59. Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, et al. The effects of additional pathology on the cognitive deficit in Alzheimer's disease. J Neuropathol Exp Neurol 1997;56:165-170.

60. Forette F, Seux M-L, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-1351.

61. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia : a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001;8:361-362.

62. Erkinjuntti T, Kurtz A, Gauthier S, Bullock R, Lillenfield S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease:a randomised trial. Lancet 2002;359:1283-1290.

63. Pratt R, Perdomo CA. The Donepezil Study Group. Results of clinical studies with donepezil in vascular dementia. Am J Geriatr Psychiatry 2002;10:S. 88-89.

64. Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet 1984;2:1262-1265.

65. Korczyn AD. Dementia in Parkinson's disease. J Neurol 2001;248:S3. 1-4.

66. Kurlan R, Richard IH, Papka M, Marchall F. Movement disorders in Alzheimer's disease : More rigidity of definitions is needed. Mov Disord 2000;15(1):24-29.

67. Wragg RE, Jeste DV. Overview of depression andpsychosis in Alzheimer's disease. Am J Psychiatry 1989;146:577-587.

68. Burns A. In: Katona C, Levy R, editor. Psychosis in dementia of the Alzheimer type. Delusions and Hallucinations in Old age London: Gaskell. 228-242. Royal college of psychiatrists.

69. Devanand DP. In: Gauthier S, Cummings JL, editor. Depression in dementia. Alzheimer's disease and related disorders annual 2001;London: Martin Dunitz. 97-123.

70. McAllister TW. Overview:pseudodementia. Am J Psychiatry 1983;140:528-533.

71. Reding MJ, Haycox J, Wigforss K, Brush D, Blass JP. Follow up of patients referred to a dementia service. J Am Geriatr Soc 1984;32:265-268.

72. Mortimer JA, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Head trauma as a risk factor for Alzheimer's disease:a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20:S28-S35.

73. Mayeux R, Ottman R, Maestre G, Ngai T, Tang MX, Ginsberg H, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45:555-557.

74. Joyce E. In: O'Brien J, Ames D, Burns A, editor. Dementia associated with alcoholism. Dementia 2000;2nd ed. London: Arnold. 799-811.

75. Victor M, Adams RD. In: Vinken PJ, Bruyn GW, Klawans HL, editor. The alcoholic dementias. Handbook of clinical neurology, Vol 2 Amsterdam: Elsevier Science Pubilishers. 335-352.

76. Sachdev P, Trollor J, Looi JCL. In: Qizilbash N, Schneider LS, Chui H, editor. Alcohol-related dementia. Evidence-based dementia practice Malden: Blackwell Science Ltd. 620-621.